You are here:
LinkedIn-button

News

Check here for our latest news

Press Release

Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced…

Intravacc publishes positive phase I Shigella conjugate vaccine data
  • High medical need for Shigella vaccine
  • Over 250 million infections worldwide annually
  • Vaccine was well tolerated and induced a significant increase in functional antibodies
  • Data published in prestigious journal The Lancet Infectious Diseases
Read more

Press Release

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer Bilthoven, The Netherlands, 5 November 2020 – Intravacc, a global leading contract development and manufacturing organization of viral and bacterial vaccines, today announced the appointment of Prof. Dr. Virgil Schijns,…

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer
Read more

Press Release

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our…

Intravacc 2.0
  • New website and branding
  • Matches Intravacc’s aspiration to become a leading vaccine CDMO
  • We welcome your feedback on our new website
Read more

Press Release

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine Bilthoven, The Netherlands, 8 September, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract…

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
  • Growing concerns about global spread of this respiratory enterovirus
  • Vaccine to protect children from Acute Flaccid Myelitis
  • Development of inactivated EV D68 vaccine, through to Phase I clinical testing
Read more

Press Release

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx,…

Intravacc and Therapyx jointly develop the world's first prophylactic gonorrhea vaccine
  • Gonorrhea is the second most common bacterial infectious disease worldwide
  • Vaccine based on IL12 in combination with intravacc’s gonorrhea OMV targeting mucosal immunization
  • Induce an adaptive immune response for long term protection against the gonorrhea bacteria
  • Mucosal vaccine platforms offer a broader perspective also for respiratory virus vaccines, such as Covid-19 and influenza
Read more

Press Release

Intravacc’s candidate RSV vaccine demonstrates safety in phase I trial Bilthoven, The Netherlands, 18 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine,…

Intravacc's candidate RSV vaccine demonstrates safety in phase I trial
  • High unmet need for effective pediatric RSV vaccine
  • Continued frequent hospitalization of infected infants and risk to elderly
  • Partner orientation for further development of this RSV candidate vaccine
Read more
LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.